Editas CEO Katrine Bosley
Editas Medicine, a biotechnology startup, will begin tests of a powerful new form of gene repair in humans within two years. Speaking this week at the EmTech conference in Cambridge, Massachusetts, Editas CEO Katrine Bosley said the company hopes to start a clinical trial in 2017 to treat a rare form of blindness using CRISPR, a groundbreaking gene-editing technology.
Continue reading… “Biotechnology startup will begin testing CRISPR gene editing on humans in 2017”
